©The Author(s) 2025.
World J Gastrointest Surg. Oct 27, 2025; 17(10): 105360
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.105360
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.105360
Table 2 Post treatment outcomes among studied groups
| Indicator | Group A | Group B | P value |
| CR (%) | 54.5 | 75.0 | 0.012 |
| PR (%) | 36.4 | 15.0 | 0.008 |
| SD (%) | 9.1 | 7.0 | 0.045 |
| Mean AFP after SBRT (ng/mL) | 176.5 ± 35.0 | 18.4 ± 4.5 | 0.003 |
| Mean ALP after SBRT (U/L) | 120.0 ± 20.0 | 90.0 ± 15.0 | 0.007 |
| Mean ALT after SBRT (U/L) | 45.0 ± 10.0 | 30.0 ± 5.0 | 0.005 |
| Mean AST after SBRT (U/L) | 50.0 ± 12.0 | 35.0 ± 6.0 | 0.006 |
| Mean GGT after SBRT (U/L) | 60.0 ± 15.0 | 40.0 ± 8.0 | 0.004 |
| Mean bilirubin after SBRT (mg/dL) | 1.2 ± 0.3 | 0.8 ± 0.2 | 0.009 |
| Mean platelets after SBRT (103/μL) | 200 ± 40 | 220 ± 30 | 0.021 |
| Mean WBC after SBRT (103/μL) | 6.0 ± 1.0 | 5.5 ± 0.8 | 0.034 |
| Mean hemoglobin after SBRT (g/dL) | 12.0 ± 1.5 | 13.0 ± 1.0 | 0.015 |
- Citation: Chen L, Wang L, Wang H. Comparison of stereotactic body radiotherapy following transcatheter arterial chemoembolization vs transcatheter arterial chemoembolization alone in hepatocellular carcinoma. World J Gastrointest Surg 2025; 17(10): 105360
- URL: https://www.wjgnet.com/1948-9366/full/v17/i10/105360.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i10.105360